STCube has collaborated with Steven H. Lin, MD, a clinician at MD Anderson Cancer Center, in developing a platform to identify new immune-checkpoint proteins. STCube entered into a Sponsored Research Agreement with Professor Mien-Chie Hung, also at MD Anderson Cancer Center, directed to investigation of protein glycosylation, culminating in a platform to develop a distinct class of antibodies. Dr. Hung is currently serving as the President at China Medical University, Taiwan, and the collaboration is still on-going in his new capacity. Further, small molecule drug candidates are currently being developed in cooperation with Dr. Stephen W Byers at Georgetown University.
In order to commercialize cancer immunotherapies and anti-viral therapies for infectious diseases, various collaborations with industrial institutions such as Samsung Biologics, Canada based Nexelis, and U.S. based Weinberg Group, are currently on-going. Regarding certain pipeline products, collaborations involving potential joint development and/or technology transfer are currently under discussion with several globally recognized biopharmaceutical companies.
STCube is part of a collaborative network in which top-notch clinicians and scientists from world-renowned hospitals and clinical and research organizations take part.
The company continually seeks opportunities to collaborate with other domestic and foreign academic, industrial, and clinical institutions.
Please contact firstname.lastname@example.org for inquiries.